Presenter of 1 Presentation
ASSOCIATION BETWEEN CHANGE IN HBA1C AND PROFESSIONAL CGM USE IN ADULTS WITH TYPE 2 DIABETES ON NON-INSULIN THERAPIES–A REAL WORLD EVIDENCE STUDY
Abstract
Background and Aims
Previous studies have shown clinical benefits in patients who used professional Continuous Glucose Monitor (CGM). However, the effect of professional CGM use in non-insulin Type-2 Diabetes (T2D) patients having poor glycemic control in real world settings has not been studied. We examined the association between HbA1c and professional CGM in T2D patients with poor glycemic control using multiple non-insulin therapies.
Methods
This retrospective analysis used healthcare claims data from Optum® Clinformatics,® comprised of commercial and Medicare Advantage members between 01-January 2018 to 31-October 2020. T2D patients ≥ 18 years of age were identified using ICD-9/ICD-10 codes having an HbA1c between 7.8–10.5%, using ≥ 2 non-insulin therapies, with no prior CGM or professional CGM use, and 6-months of continuous enrollment pre and post index date. Index date was defined as acquisition of professional CGM identified through CPT codes 95250 and 95251. The outcome was mean HbA1c change between baseline and up to 6-months post-index date.
Results
Data from 15,474 eligible patients were assessed (Professional CGM users, n=677; Non-users, n=14,797). A significant decrease in mean HbA1c from baseline was observed for professional CGM users (-0.78) vs. non-users (-0.32), p <0.0001 (difference-in-differences estimate, -0.50; 95% CI,-0.61 to -0.39; p <0.0001).
Conclusions
Findings suggest T2D patients with poor glycemic control using multiple non-insulin therapies may benefit from professional CGM resulting in reduction in HbA1c over a 6-month period compared to usual care. Professional CGM can inform clinicians about their patients’ glycemic patterns and help to tailor diabetes management strategies for patients.